Furazolidona

Quick links

Choose a section

Quick links to important sections

Advertisements

Furazolidona

Advertisements
Advertisements

Method of action: Antidiarrheal, Antiprotozoal

Treatment option: Diarrhea, Dysentery, Enteritis

Advertisements

Overview of Furazolidona

Property Description
Active Ingredient Furazolidone
Form Oral tablet, liquid suspension
Pharmacological Class Nitrofuran derivative
General Purpose Anti-infective (Antibacterial/Antiprotozoal)
Origin Synthetic (chemically manufactured)

What Type of Medicine is Furazolidone?

Furazolidone is a synthetic medication that belongs to the nitrofuran derivative pharmacological class, clinically recognized for its broad-spectrum activity against various microorganisms. The International Nonproprietary Name (INN) for this active ingredient is Furazolidone, which is available under various brand names globally.

This medicine is primarily an anti-infective agent used to target infections in the gastrointestinal tract. It is used in the management of acute bacterial diarrhea and other parasitic gut issues. This dual action against both bacteria and protozoa positions it as a versatile prescription option for specific severe infectious causes of digestive illness.

Composition and Origin: Is Furazolidone Natural or Synthetic?

Furazolidone is a wholly synthetic compound, manufactured through a controlled chemical process to ensure high purity and consistent strength. This synthetic origin is a key differentiating factor from anti-infective agents derived from natural organisms, such as molds.

When taken as an oral tablet or liquid suspension, the medicine is designed for localized action. The drug exhibits poor absorption into the bloodstream, which allows the majority of the active substance to concentrate directly in the gastrointestinal tract where the target microbes reside. This mechanism ensures the therapeutic effect is focused at the site of infection.

The Purpose of Furazolidone: A Focused Anti-Infective Action

The fundamental purpose of Furazolidone is the active destruction of susceptible pathogens—it operates as a microbicidal agent. This action allows it to clear the source of the infection, which is essential for recovery from acute gastroenteritis. By eliminating the harmful organisms, Furazolidone helps restore the normal function of the digestive system.

Regulatory References

  1. NIH via PubMed
Advertisements

What side effects are possible with Furazolidona?

Possible side effects and safety information

The safety profile for Furazolidone is systematically documented in regulatory labeling, covering a range of adverse reactions classified by frequency and affected body systems.

Documented Adverse Reactions and Safety Characteristics

The most frequently cited adverse reactions in official documents are centered on the Gastrointestinal System, including nausea, vomiting, abdominal pain, diarrhea, and generalized malaise, often classified as common or occasional in clinical use summaries. Effects concerning the Nervous System, such as headache and dizziness, are also documented.

System-Organ Class Key Adverse Reactions (As Listed)
Blood and Lymphatic System Hemolytic anemia, methemoglobinemia, leukopenia
Immune System/Hypersensitivity Urticaria (hives), fever, rash, fall in blood pressure
Nervous System Peripheral neuropathy, headache, dizziness

Serious and Time-Related Safety Constraints

The medicine carries specific constraints documented in regulatory labeling. The risk of hemolytic anemia is a major constraint, and the drug is officially contraindicated for infants under 1 month of age due to the possibility of this condition resulting from immature enzyme systems. Patients with Glucose-6-phosphate dehydrogenase (G6PD) deficiency are also noted as a susceptible population.

Peripheral neuropathy is a recognized safety concern associated with extended or prolonged use of the medication. Additionally, due to its Monoamine Oxidase Inhibitor (MAOI) activity, a potential hazard for hypertensive crisis exists when the drug is administered in excess of recommended dose or duration. The official safety profile also includes the possibility of a Disulfiram-like reaction if alcohol is ingested during therapy and for four days following the last dose.

Advertisements

Overdose and Emergency Response

Documented Overdose Manifestations

The official regulatory documents define the required response and clinical profile for Furazolidone overdosage. Overdose may present with acute signs such as nausea and emesis (vomiting), particularly when the maximal daily dosage is exceeded. Systemic toxicity, associated with higher exposure to the nitrofuran class, can manifest as more severe neurological effects, including tremors and convulsions (seizures), as well as peripheral neuritis. General gastrointestinal disturbances are also documented presentations.

Severe Outcomes and Emergency Actions

A critical regulatory concern is the potential hazard of hypertensive crisis, which is linked to the accumulation of monoamine oxidase (MAO) inhibition when the drug is taken in doses larger than officially recommended or for a duration exceeding five days.

In cases of suspected massive overdose, immediate medical attention is required. Official prescribing information states that no specific antidote is known for Furazolidone overdosage. Management is therefore constrained to symptomatic and supportive treatment, a procedure that must be instituted immediately. Early gastric lavage may be utilized as a supportive measure. Medical evaluation is also required if use exceeds the recommended dosage or duration due to the specific risk of MAO inhibition.

Advertisements

Therapeutic Uses of Furazolidona

Quick Facts: Therapeutic Areas

  • Gastrointestinal Infections: May be used in the management of diarrhea and enteritis.
  • Protozoal Conditions: Used to address infections caused by certain protozoa, such as giardiasis.
  • Bacterial Infections: May address infections caused by susceptible organisms, including specific types of cholera and bacterial diarrhea.

Furazolidona may be indicated for the management of certain intestinal infections caused by susceptible bacteria and protozoa. Its primary therapeutic domains include addressing diarrhea and enteritis associated with these microbial organisms. This medication may be a component of regimens intended to help control the symptoms and course of conditions such as cholera and giardiasis.

It provides antimicrobial activity and is one of the agents used to manage infections of the gastrointestinal tract. The selection and use of this drug should always be determined by a healthcare provider, and it may be combined with other therapies depending on the specific infection.

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Furazolidona — official regulatory information

Eligibility scope

Section Content
Populations for whom use is allowed (as stated in label) Adults and children 1 month of age and over who do not have documented contraindications.
Populations for whom use is not recommended (if applicable) Infants up to 1 month of age.
Populations for whom use is contraindicated Patients with known hypersensitivity to the drug or other nitrofuran derivatives.
Age-related eligibility rules Use is not recommended in infants under 1 month. There is no specific information comparing use in geriatric patients with other age groups.
Condition-specific eligibility rules Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency is a key non-eligibility factor. Official labels do not contain explicit contraindications for renal or hepatic impairment.
Pregnancy and lactation eligibility status (if explicitly documented) Pregnancy: Safety during childbearing age has not been established. Lactation: Breastfeeding is not recommended for nursing infants up to 1 month of age.
Eligibility-related restrictions Use is subject to close monitoring in patients with G6PD deficiency, and the drug must be discontinued if hemolysis occurs.

Eligibility classifications (high-level)

Classification Content
Eligibility severity classification (as defined in official documents) Contraindicated (Infants < 1 month, Hypersensitivity, G6PD deficiency); Use Not Established (Geriatric, Pregnancy, Lactation).
Regulatory basis (EMA / FDA / etc.) Official Prescribing Information / Summary of Product Characteristics, reflecting requirements from authorities such as the FDA.
Eligibility-context constraints (as defined in official documents) Enzymatic deficiency (G6PD) and developmental stage (Neonatal) are specific constraints on population eligibility.

Resulting eligibility structure

Official eligibility statements:

  • The medicine is contraindicated in infants up to 1 month of age.
  • Patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency are contraindicated or should not be given Furazolidone.
  • Use is not established in women of childbearing potential or during pregnancy.
  • The drug is contraindicated in patients with a known hypersensitivity to Furazolidone.
  • No specific information comparing use of the drug in geriatric patients with other age groups is available.

Connection to the overall eligibility profile

Official regulatory documents define the eligible population as adults and children 1 month of age and older who do not possess specific intrinsic contraindications. Eligibility is strictly limited by the presence of certain patient factors, including an absolute prohibition for infants under 1 month and patients with G6PD deficiency due to the documented risk of a specific hematological adverse effect.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This information details the officially documented interaction profile of Furazolidona, derived strictly from governmental regulatory documents.

Medicinal Product and Class Interactions

Category Interaction Note
MAO Inhibitors Concurrent use with other Monoamine Oxidase (MAO) Inhibitors is advised against.
Sympathomimetics Use with indirect- or mixed-acting sympathomimetic amines (e.g., ephedrine, phenylephrine) may precipitate severe hypertensive reactions.
Serotonergic Agents Co-administration with agents that increase serotonin levels (e.g., tricyclic antidepressants) carries a risk of heightened adverse effects.
CNS Depressants Combined use may increase the risk of central nervous system depression.

Non-Medicinal Product Interactions and Restrictions

Substance Restriction/Constraint
Alcohol Consumption of alcohol or alcohol-containing preparations is prohibited due to the risk of a disulfiram-like reaction. This restriction must continue for at least 4 days after discontinuation of the medicine.
Foods/Beverages Ingestion of tyramine- or other high pressor amine-containing foods and beverages is advised against due to the risk of sudden and severe hypertensive reactions. Dietary restrictions must be maintained for at least 2 weeks after stopping this medicine.

Note: These interaction constraints define the necessary requirements for safe use, based on the drug's properties as an MAO inhibitor. Infants up to 1 month of age should not receive the drug due to the possibility of producing hemolytic anemia, a risk linked to potential underlying G6PD deficiency.

Advertisements

Mechanism of Action

Furazolidone functions as a highly specific prodrug that exerts a microbicidal effect, meaning it actively causes the destruction of the target pathogen.

Step 1: Selective Reductive Activation by Pathogens

The drug's action begins inside susceptible pathogens (bacteria and protozoa) that contain nitroreductase enzymes. These microbial enzymes selectively reduce Furazolidone, transforming the inactive compound into highly reactive, toxic intermediates. This initial step confines the drug's lethal potential exclusively within the microorganism, demonstrating pathogen-selective activation over host-cell targets.


Step 2: Irreversible Destruction and Metabolic Collapse

Once activated, these toxic intermediates rapidly bind to and inflict damage upon the pathogen's DNA (causing strand breaks) and numerous essential enzyme systems crucial for energy production and cellular respiration. This combined assault halts DNA replication and causes metabolic collapse, leading directly to irreversible microbial cell death within the gut lumen.

Advertisements

Dosage and Administration Information

How to Use Furazolidone: Administration Guidelines

Furazolidone is an anti-infective medication with specific instructions for administration and dosing, intended for the treatment of susceptible gastrointestinal infections.

Approved Route and Dosage Forms

The medicine is used via the oral route of administration. It is typically available as a 100 mg oral tablet (often scored) and a liquid suspension for oral use.

Standard Adult Dosing and Frequency

Treatment regimens are based on a fixed dose of 100 milligrams (mg) per administration. Furazolidone is generally taken four times a day (q.i.d.) for labeled indications to maintain therapeutic concentrations.

Indication Standard Adult Dose Frequency Typical Duration
Bacterial Diarrhea / Cholera 100 mg q.i.d. 5 to 7 days
Giardiasis 100 mg q.i.d. 7 to 10 days

Administration Requirements and Special Populations

  • With or Without Food: Doses may be taken with food to help reduce the potential for stomach discomfort.
  • Suspension Preparation: The liquid formulation is shaken well before use, and the dose is measured using an accurate measuring device.
  • Pediatric Use: The medication is not recommended for infants under one month of age. For children over one month, dosing is determined by a healthcare provider based on the child's body weight, typically in the range of 1.25 mg to 2 mg per kilogram per day.
  • Course Completion: To achieve the intended therapeutic outcome, the entire duration of the prescribed treatment is completed, even if symptoms begin to improve sooner.
Advertisements

Recent Clinical Evidence

Furazolidona: Recent Clinical Evidence

Efficacy in Infectious Conditions

Furazolidona, a nitrofuran antimicrobial agent, has been studied primarily for its effects against certain bacterial and protozoal infections in the gastrointestinal tract. Research has explored whether furazolidone may affect outcomes in conditions such as bacterial enteritis and giardiasis. Studies have investigated the drug's activity by measuring changes in parasite load or symptom reports in participants with acute diarrheal illness.

Evidence from clinical trials often focuses on short-term efficacy measures. For instance, some studies examined resolution rates of Giardia lamblia infection, noting that participant results varied across trials and geographical regions. A systematic review of trials for specific indications suggested that furazolidone was one of several treatment options evaluated for specific protozoan infections, but it often noted that the evidence base remains limited and characterized by high variability among studies.


Safety Profile and Tolerability Research

Research on furazolidone's safety profile typically includes analysis of adverse events (AEs) reported during clinical use. Studies have assessed common side effects, which may include nausea, vomiting, and abdominal pain. A notable area of research concerns the potential for monoamine oxidase (MAO) inhibition. This inhibitory activity is central to safety research, as it requires careful consideration of potential drug and food interactions.

Clinical documentation notes on the use of furazolidone often include cautions regarding its combination with certain foods or medications that may lead to hypertensive crises. Further research has examined the drug's use in pediatric populations, though findings regarding comparative safety and efficacy in children require cautious interpretation due to the limited number of large-scale, controlled studies.

Key Studies & References

  1. World Health Organization (WHO) Model Prescribing Information: Drugs Used in Parasitic Diseases (Second Edition) - Furazolidone Monograph
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Furazolidona (FAQ)


Q: Why does Furazolidona sometimes cause nausea or stomach upset?

Official documentation lists gastrointestinal issues, such as nausea, vomiting, and abdominal pain, as common adverse reactions. Official documentation indicates these side effects are common, which may be related to the drug's localized anti-infective activity in the gastrointestinal tract.


Q: Is it normal to have dark urine while taking Furazolidona?

Official patient information notes that it is common for this medication to cause urine to change color, often turning a dark yellow or harmless brown. This color change is expected, and it is usually considered harmless. If you are concerned, speak with a healthcare provider.


Q: How long does Furazolidona typically stay in your system after stopping?

While the exact time for full drug clearance is not generally listed, official warnings indicate the drug's activity persists. Regulatory instructions require avoidance of alcohol for at least 4 days and avoidance of tyramine-containing foods for at least 2 weeks after the last dose, reflecting the time needed for the drug to clear the system.


Q: Can Furazolidona affect the results of any common lab tests?

Official documentation reports events like hemolytic anemia and methemoglobinemia. These hematological effects would be important for your provider to monitor using standard blood tests.


Q: What are the signs of a serious allergic reaction to Furazolidona?

Serious reactions listed in official warnings include hypersensitivity symptoms such as hives (urticaria), fever, rash, and a fall in blood pressure. Official warnings state that symptoms such as difficulty breathing or swelling are signs of a severe reaction. Immediate medical attention is necessary if these occur.


Q: Can Furazolidona cause changes in mood or sleep?

Official documentation lists effects on the Central Nervous System (CNS), such as dizziness and headache. The product information also warns of risks when the drug is combined with CNS depressants. However, specific changes to mood or sleep are not explicitly listed as adverse reactions.


Q: Do any herbal supplements commonly interact with Furazolidona?

Regulatory documents advise against combining Furazolidona with other MAO Inhibitors and agents that increase serotonin levels, as this can increase the risk of serious side effects. This restriction applies to any product, including certain herbal supplements, that may have similar MAO-inhibiting or serotonin-increasing activity.


Q: How does the mechanism of action of Furazolidona affect protozoa?

The drug is effective against protozoa (single-celled parasites) by being selectively activated inside the organism via specific enzymes. Once activated, the drug becomes toxic and destroys the protozoa's DNA and essential enzyme systems, leading to the destruction of the infectious organism.


Q: Are headaches a common side effect of Furazolidona?

Headaches are listed in official documentation as a recognized adverse reaction affecting the nervous system. However, official information does not typically categorize the frequency of headaches (e.g., as 'common' or 'rare') in a standard numerical or percentile manner.


Q: What happens if I miss a dose of Furazolidona?

Official patient information addresses what to do for a missed dose, generally advising users to follow the schedule carefully and avoid taking double doses. Specific steps should be discussed with the prescribing healthcare provider.


Q: Is Furazolidona safe to use for short-term travel-related diarrhea?

Official indications state the drug is for susceptible bacterial diarrhea. Only a healthcare provider can determine if the cause of an infection, including one acquired during travel, is appropriate for treatment with this medication.


Q: Are there long-term side effects to worry about with Furazolidona?

Regulatory warnings specifically note that Peripheral Neuropathy is a recognized safety concern associated with the extended or prolonged use of Furazolidona. Due to the potential for peripheral neuropathy, treatment duration is generally limited as outlined in the prescribing information.


Q: What should I do if the side effects from Furazolidona are bothering me?

Official patient guidance notes that if side effects become bothersome or concerning, a healthcare provider should be contacted for appropriate management advice.


Q: Does Furazolidona require a prescription in most countries?

Furazolidona is classified as a prescription-only medicine by major regulatory authorities like the FDA. While regulatory status may differ in specific jurisdictions, it is generally not available without a prescription.


Q: Is it necessary to take Furazolidona with food?

Official administration requirements state that doses may be taken with food to help minimize the potential for stomach discomfort. This indicates that taking it with food is optional and not strictly necessary for the drug to work.


Q: Can patients with liver issues take Furazolidona safely?

Official regulatory labels do not list hepatic (liver) impairment as an explicit contraindication. The decision regarding safe use in patients with liver issues is determined by a healthcare provider.


Q: Is there a maximum time someone can safely take Furazolidona?

The standard treatment course is short (5 to 10 days). The label warns of the risk of developing Peripheral Neuropathy with prolonged use, indicating that treatment duration must be limited.


Advertisements

How should Furazolidona be stored and disposed of?

How to Store and Dispose of Furazolidona

Storage & Disposal Parameter Official Regulatory Requirement
Storage Temperature: Store at controlled room temperature (15 C to 30 C), away from heat [Source: NIH/MedlinePlus, USP/FDA-aligned monographs].
Environmental Protection: Must be protected from moisture and light; keep from freezing [Source: NIH/MedlinePlus].
Container Requirements: Store in a closed, tight, and light-resistant container [Source: USP/FDA-aligned monographs].
Child Safety: Keep the medicine out of the reach and sight of children [Source: NIH/MedlinePlus].
Disposal Instructions: Do not keep outdated medicine; dispose of unused product responsibly, preferably through a drug take-back program or by securing it in household trash (do not flush) [Source: FDA guidance, NIH/MedlinePlus].

The official storage profile mandates that Furazolidone be kept at room temperature and strictly protected from light, moisture, and freezing to preserve its stability. The product must remain in its proper container and be stored securely away from children. Disposal protocols require that any unused or expired medication not be kept and be discarded according to regulatory guidelines, avoiding wastewater systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Furazolidona found in:

A-Z Index: